Investing in the most ambitious Medical Cannabis Supplier
Import and wholesale of high quality finished medical cannabis products for Danish patients.
STENOCARE signs agreement with new prominent supplier, PANAXIA and announces imminent product approval application filing
STENOCARE: Notification of changes in major shareholding and increased holding of own shares.
Founded in Denmark in 2017, STENOCARE sole purpose is being part of the Danish four-year Programme for medical cannabis products to patients. The company is operating in a highly regulated market under the jurisdiction and control of the Danish Medical Agency – where the products are only legally available via prescription from a physician to a patient.
STENOCARE has their headquarter in Denmark, and a wholly owned subsidiary – STENOCARE Ireland Ltd – in Ireland.
STENOCARE vision is to provide high quality medicinal cannabis that gives patients better quality of life
STENOCARE mission is to provide uniform medical cannabis products grown and produced in hygienic climate rooms without the use of pesticide
The STENOCARE 2.0 strategy is building assets within three categories that supplement each other and are important for the success of the company:
- Commercial assets; having medical cannabis products approved in the very strict regulatory regime in Denmark enable the company to leverage this asset in Denmark and future markets. With a multi-supplier approach for sourcing patient-ready products, this is a solid platform for the planned international expansion beyond Denmark.
- Partnership assets; with doctors and patients looking for more product choice for treatment with prescription-based medical cannabis – the company will enter into research and development partnerships to bring exclusive and innovative medical cannabis product to market that differentiate its product portfolio.
- Supply chain assets; where the company control the entire value chain and build internal expertise with its own indoor cultivation facility. Having the capability of producing high quality medical cannabis that is controlled and fully documented from seed to sales in the indoor setup that emulate pharma principles is an important asset to be successful in the premium segment that STENOCARE is serving in their markets. This will enable it to supply high quality products that meet the requirements of patients, medicines agencies and the pharma industry
These three categories leverage the proven results from the STENOCARE 1.0 strategy, that made the company a first-mover in the Danish medical cannabis industry by securing regulatory approvals from The Danish Medicine Agency.
The company has been granted (1) approval to import/manufacture/Distribute medical cannabis products, (2) approval to cultivate and product medical cannabis products, (3) approval to handle activities with euphoriant substances – and (4) approval to have STENOCARE medical cannabis oil and capsule products accepted on the Danish Medicine List. The company has cultivated without the use of pesticides in their Danish small scale facility and am in the process of implementing a larger scale indoor state-of-art cultivation facility that build on best practices from greenhouse and clean-room production.
Profitable Year-End Report
Join the CEO of STENOCARE in his comments on the profitable Year-End Report 2019 and his reflections for the future growth of the company.
STENOCARE is a ”company to watch” for 2020
The new edition of The European Cannabis Report 5th Edition was published February 2020, and in the section “Companies to Watch” the Report profile STENOCARE as one of few medical cannabis leaders in Europe:
Quote from the Report:
“The company is now a leader in the European market; its production and distribution network in Denmark was profitable in 2018 and is currently expanding to Ireland among other emerging markets. This is notable as even large companies have struggled to produce a profit in the early years of the industry”
The European Cannabis Report is a comprehensive source of information covering each European country and its status/progress with medical cannabis. Therefore the Report offer a good insight into market opportunities, key stakeholders and how medical cannabis is applied for treatment of patients in Europe. The European Cannabis Report is free and is published by Prohibition Partners. Access the Report HERE
Thomas Skovlund Schnegelsberg, CEO of STENOCARE A/S present the Interim Report Second Quarter 2019 and inform about the current challenges relating to STENOCARE’s Canadian partner, CannTrust. Annabella Pultz from Finwire is hosting the event.
STENOCARE celebrated as the Best IPO 2018 at the ceremony hosted by SvD Börsplus.
The STENOCARE Executive Management team, ring the bell at Spotlight Stock Market to start first trade of STENOCARE stocks.
Listing ceremony of the first medical cannabis company in Europe.
Our strategy to become a leading high-end brand in Europe is fueled by the competitive advantage, that we are operating under very strict regulatory control by the medicines agencies
chairman OF THE BOARD
Dates for release of financial information